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  The value and necessity of engaging patients during the development and lifecycle of medicines 
is increasingly recognised and many discrete initiatives are underway or planned.
  Though complementary, these separate activities have resulted in a fragmented patient 
engagement (PE) landscape. Investment in a holistic, integrated and sustainable initiative is 
required to cover the entire medicines lifecycle and to connect stakeholders across geographies. 
  Patient Focused Medicines Development (PFMD; www.pfmd.org) is a global, multi-stakeholder 
collaboration of health stakeholders taking a rational four-step approach towards co-creation of 
a meta-framework for PE: (1) mapping and connecting the PE landscape to learn from existing 
efforts; (2) multi-stakeholder co-creation of PE guidance and good practice identification; (3) 
development and piloting of a strawman meta-framework for PE; and (4) refinement of the 
strawman meta-framework to create an actionable meta-framework and implementation tools. 
  This poster focuses on the development of the PE Quality Guidance and identification of good 
practice examples.
PE Quality Guidance co-creation
  Multi-stakeholder working groups (WGs) and task forces (TFs) were established for Guidance 
co-creation. Published literature and existing frameworks were reviewed (2011-2016). 
SYNaPse (a PE mapping and networking platform developed by PFMD) was used to identify 
unpublished PE initiatives and initiative owners were invited to WGs/TFs. 
  A preliminary PE Quality Guidance tool (incorporating PE Quality Criteria) was developed 
by WGs/TFs in an iterative process, through: review of published material and landscape 
analysis to identify unmet needs; incorporation of participants’ PE experience to identify and 
prioritise needed actions; and owners retrospectively applying the draft Guidance to their 
initiatives as a pressure-testing evaluation (Figure 1). 
Co-creation workshops and participants
  Nine WG/TF/Core Team meetings were held (Nov 2016-June 2018) involving 76 unique 
participants, representing 51 organisations (including patient charities, academic 
researchers, funders, pharmaceutical companies).
Mapping and connecting the PE landscape
  A total of 239 publications were identified covering the period of 2011-2016 using PE-
relevant search criteria (in PubMed and British Medical Journal Open), of which 25 were 
relevant or somewhat relevant. An additional 8 resources (including seven conceptual 
frameworks/models1-10) were included to capture approaches outside of the search 
period.
Multi-stakeholder co-creation of PE Quality Guidance
  WGs/TFs adapted and augmented the characteristics from the frameworks into the PE 
Quality Guidance. The PE Quality Guidance is organised around seven PE Quality Criteria 
that represent key elements of quality PE. These criteria have drawn primarily from 
guidance and frameworks developed by INVOLVE8-10 and enriched with the analysis of PE 
initiatives collected in SYNaPsE and from the WG/TF/Core Team.
Structure of the PE Quality Guidance
  The PE Quality Guidance is structured to be used either as an aid to planning new PE 
projects, or to facilitate assessment of ongoing or completed PE projects. It incorporates 
four components to capture: background information, quality of PE, outcomes and 
lessons learned.
  The PE Quality Guidance proposes seven PE Quality Criteria (Table 1) to aid assessment 
of the quality of PE in specific projects. 
  The PE Quality Criteria: describe core values that a good PE practice should consider 
including in its processes; provide a set of principles to improve consistency in PE 
practices; and enable systematic assessment and communication of project outcomes. 
  For each criterion, there is a definition, a rationale and questions for consideration 
by the initiative owners that can be used for planning and/or evaluation purposes. 
The relevance of each PE Quality Criterion may differ from project to project and this 
variation can be captured within the tool.
Using the PE Quality Guidance
  The PE Quality Guidance contains tools for assessment of initiatives that are either 
planned or in preparation (scenario 1) or ongoing or completed (scenario 2) against the 
PE Quality Criteria. The tools can be accessed directly from the PE Quality Guidance and 
completed online (Figure 2). 
  For each scenario, the tool captures basic background information and then focuses on 
each of the PE Quality Criteria. 
  Each criteria section has
  A detailed explanation of the criterion
  Supporting questions to help identify specific actions
  Illustrative examples of that criterion in practice 
  A link to relevant resources 
  The section on PE Quality Criteria is followed by the ‘Results and outcomes’ section. 
A final section on ‘Lessons learned’ is available in the tool for ongoing or completed 
projects (Table 2). 
Public consultation on draft PE Quality Guidance
  A public online, survey-based consultation on the draft PE Quality Guidance was undertaken 
(from 20 November 2017 to 1 January 2018) to gather wider input from PE stakeholders.
  Consultation was invited via the PFMD website and across stakeholder groups via WG, TF and 
PFMD networks; and through advertising (21,589 reach), media (40,259 reach) and a social 
media campaign. Feedback from the public consultation and from a separate focus group was 
used to refine the PE Quality Guidance.
Identification of good practice examples 
for the Book of Good Practice (BOGP)
Examples of good practice were collected through screening of initiatives in SYNaPsE and via TF 
and PFMD networks. The review and selection process for inclusion in the BOGP was anonymised 
to avoid bias and was undertaken by a multi-stakeholder PE Meta-framework Core Team.
Figure 1: Process for development of the PE Quality Guidance (PEQG) tool
  METHODS
  BACKGROUND   RESULTS: PE QUALITY GUIDANCE CO-CREATION
  RESULTS: PUBLIC CONSULTATION ON DRAFT PE QUALITY GUIDANCE   CONCLUSIONS
Quality Criterion Explanation
1. Shared purpose
This refers to the project’s aims and outcomes that all stakeholders taking part should 
agree on before starting the project. It can facilitate open exchange of views, and help 
define the scope and objectives of the project.
2. Respect and 
accessibility
This refers to (1) respecting each other, and respectful interactions within the project to 
be established among partners, and (2) openness to and inclusion of individuals and 
communities (to the project) without discrimination. It should consider practical ways of 
enabling different stakeholders with different needs to take part in the project
3. Representativeness 
of stakeholders
This refers to the mix of people you involve, which should reflect the needs of the 
project, and the interests of those who may benefit from project outputs (for example, 
target population). It should consider diversity in expertise, experience, demographics, 
and other relevant criteria for inclusion.
4. Roles and 
responsibilities
This refers to the need for agreed – and ideally co-created – roles and responsibilities, 
in writing. It should indicate that all aspects of project needs will be established upfront 
and revisited regularly.
5.Capacity and 
capability for 
engagement
This refers to (1) capacity as having relevant and dedicated resources from all 
stakeholders (e.g., stakeholders allocating sufficient time to allow genuine engagement); 
and (2) capabilities required for all stakeholders to enable meaningful engagement (e.g., 
the required level of knowledge or expertise and training).
6. Transparency in 
communication and 
documentation
This refers to the establishment of a communications plan and ongoing project 
documentation that can be shared with stakeholders. It should consider timeliness of 
communication, project updates to share progress, and how outcomes will be shared to 
show how contribution of stakeholders was of value to the success of the project.
7. Continuity and 
sustainability
This refers to the smooth progression of the project, as well as efforts to maintain 
ongoing relationships with stakeholders. It should consider the role of stakeholders 
beyond a single project.
Section Use this section to...
Section 1: Basic 
information
  Describe the project objectives, desired outcomes and methods used
  Identify which phases of medicines development, lifecycle or disease 
management the project covers
  Describe which stakeholders the project involves
Section 2: 
Quality of PE
  Systematically ‘walk through’ each PE project, identifying and detailing 
specific tactics or approaches to achieve project aims
Section 3: 
Results and 
outcomes
  Capture expected or desired outcomes for planned projects
  Capture actual results and details of methods used to collect them for 
ongoing or completed projects
Section 4: 
Lessons learned
  Capture experiences from the PE initiative including challenges faces 
and solutions implemented
  Document what went well and what you would do differently in future 
projects
  The public consultation on the draft PE Quality Guidance resulted in 851 website visits and 67 responses (74% completion rate) across diverse stakeholders including: 
patients/patient organisations; pharma/biotech; and research/academia. 
  The majority (69%) of responders were from Europe. Over 80% of respondents indicated that they were ‘advanced’ in terms of their PE experience (‘actively part of PE projects’).
  Of 51 respondents, the vast majority (range 85% to 96%) agreed or strongly agreed that: the PE Quality Criteria are useful for achieving quality PE practice; the language 
used is comprehensive and easy to understand; and the format is clear (Figure 3). 
  The co-created PE Quality Guidance tool can be used by multiple stakeholder groups and provides a practical 
guide to improve the quality of PE during planning and development of new projects or assess the quality and 
impact of ongoing/completed projects. The good practice examples provided will support implementation of 
PE Quality Guidance. 
  PE is not ‘one size fits all’ and consequently, the PE Quality Guidance is not prescriptive, rather it is based on 
core principles that can be adapted and applied according to the unique needs of each interaction and project. 
  We urge use of, and feedback on, the PEQG by diverse stakeholders to drive improvements in PE and allow 
continuous refinement of the tool.
  The PE Quality Guidance is not an isolated tool. It is part of a wider and ongoing effort towards synergising PE 
activities for more effective, systematic and measurable PE through co-creation and implementation of a meta-
framework for PE (Figure 5). 
  Specific feedback included needing practical examples and illustrative tips based on how others have used it. The Book of Good Practice (BOGP) was created in 
response to this feedback
  The BOGP provides real-life, practical examples of PE projects that are exemplary in one or more PE Quality Criteria or overall show meaningful ways to engage 
and involve patients and other stakeholders in the medicines research and development continuum
  All cases included in the BOGP have been anonymised, and the language and content reflects the views of project owners
  Most respondents (range 65% to 84%) agreed or strongly agreed that the PE Quality Guidance could be used to: improve the quality and consistency of PE activities; 
better plan and develop PE activities; better assess the quality and impact of PE initiatives; identify gaps and opportunities for PE activities; capture and share learnings 
beyond the project or project team; and, structure work with partnering organisations (Figure 4). The feedback from the public consultation has informed the final 
versions of the PE Quality Guidance. 
Table 1: Overview of the PE Quality Criteria
Table 2: Using the PE Quality Guidance tool – step-by-step
Figure 3: General opinion on PE Quality Guidance Figure 4: Usability of PE Quality Guidance
Figure 5: Roadmap to the PE meta-framework
Completed In progress To do
Figure 2: Format of the PE Quality Guidance tools
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